Instruction for use: WobenzymI want this, give me price
Dosage form: Enteric coated tablets
L03AX Other immunostimulants
Anti-inflammatory, immunomodulating agent [Other non-narcotic analgesics, including non-steroidal and other anti-inflammatory drugs]
Anti-inflammatory, immunomodulating agent [Other immunomodulators]
The nosological classification (ICD-10)
B19 Viral hepatitis, unspecified: Anemia without hepatitis; Viral hepatitis; Viral hepatitis in children; Infection of the liver; Acute liver infection
E06.3 Autoimmune thyroiditis: Autoimmune thyroiditis Hashimoto; Thyroid Bladder Lymphadenoid; Hashimoto's disease; De Kervena thyroiditis; Goiter lymphomatous; Goiter lymphocytic; Zob Hashimoto; Lymphadenoid goiter; Thyroiditis Hashimoto; Hashimoto thyroiditis; Struma Hashimoto
G35 Multiple Sclerosis: Disseminated Sclerosis; Multiple sclerosis; Recurrent multiple sclerosis; Secondary-progressive multiple sclerosis; Exacerbation of multiple sclerosis; Mixed forms of multiple sclerosis
H20 Iridocyclitis: Recurrent Irritis; Sympathetic iridocyclitis; Sluggish posterior uveitis; Sluggish posterior uveitis; Posterior uveitis; Iridocyclitis of posterior segment of eye; Iridocyclitis and other uveitis; Irit; Keratoididocyclitis; Sharp Irritus; Uveitis; Cyclitis; Acute Iridocyclitis; Acute non-infectious uveitis
H36.0 Diabetic retinopathy (E10-E14 + with common fourth character .3): Haemorrhagic diabetic retinopathy; Diabetic retinopathy; Macular degeneration in patients with diabetes
H44.8 Other eye diseases: Hemophthalmos; Spikes of the eye
I25.9 Chronic ischemic heart disease, unspecified: CHD; Insufficiency of coronary circulation; Coronary atherosclerosis in patients with coronary artery disease
I70.2 Atherosclerosis of arteries: arteriosclerosis obliterans; Arteriosclerosis peripheral arteries; Atherosclerosis of the arteries of the lower extremities; Atherosclerosis of peripheral arteries; Atherosclerosis limbs; Occlusive disease of the lower extremities; arteriosclerosis obliterans; Arteriosclerosis obliterans of lower limb arteries; Atherosclerosis obliterans of the upper limbs; Arteriosclerosis obliterans of lower extremities; Atherosclerosis of arteries; limb arteriopathy; Arteriosclerosis obliterans limbs; arteriosclerosis obliterans
I73.1 thromboangiitis obliterans [Buerger's disease]: Berger's disease; thromboangiitis obliterans; trombangiit; thromboangiitis obliterans; Buerger's disease
I74.9 Embolism and thrombosis of unspecified arteries: Arterial embolism; Arterial thrombosis; Acute arterial thromboembolism; Acute vascular occlusion; Acute occlusion of arteries; Acute arterial thrombosis; Acute thrombosis; Acute thrombosis of peripheral arteries; Thrombosis; Thrombosis in the extracorporeal circulation; Thrombosis of peripheral arteries; Peripheral vascular thrombosis; Shunttromboz; Embolism; Embolism of peripheral arteries; Occlusive Arterial Disease
I79 lesions of arteries, arterioles and capillaries in diseases classified elsewhere: Lack of capillary circulation
I80 Phlebitis and thrombophlebitis: Diseases of peripheral vessels; Inflammation of superficial veins; Inflammatory diseases of veins; Deep venous thrombophlebitis; The disease of veins; Disease of the veins of the lower extremities; Diseases of peripheral vessels; Migrating phlebitis; Insufficiency of veins of lower extremities; Exacerbation of chronic thrombophlebitis; Acute thrombophlebitis; Acute thrombophlebitis of superficial veins; Periphlebitis; Periflebit surface; Superficial inflammation of veins; Surface thrombophlebitis; Surface phlebitis; Thrombophlebitis; Deep vein thrombophlebitis; Thrombophlebitis superficial; Phlebitis; Phlebitis of deep veins; Phlebitis of superficial veins; Phlebopathy; Chronic thrombophlebitis; Endophlebitis
I87.0 Postphlebitic syndrome: post-thrombotic venous insufficiency; Postthrombotic disease; Post thrombophlebitic syndrome; Post-thrombophlebitis; Post-thrombophlebitic syndrome; Postphlebitic syndrome; Post thrombotic syndrome; Postphlebitic syndrome (stasis syndrome)
I89.0 Lymphocyte, not elsewhere classified: Venous-lymphatic insufficiency; Lymphatic edema; Lymphedema; Lymphostasis; Lymphostasis and swelling after treatment of breast cancer; Lymphangiectatic edema; Lymphatic edema; Chronic lymphostasis; Lymphodema
J06 Acute upper respiratory tract infections of multiple and unspecified locations: Frequent colds of viral diseases; Infections of ENT organs; Acute respiratory illness of influenza nature; Pain for colds; Acute catarrhal disease; Cold; Colds; Colds; Respiratory infection; Seasonal catarrhal disease; Seasonal colds; Pain in infectious and inflammatory diseases of the upper respiratory tract; Bacterial infections of the upper respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory disease of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract with difficult to separate sputum; Inflammatory respiratory disease; Secondary infections for colds; Difficult sputum separation in acute and chronic respiratory diseases; Upper respiratory tract infections; Infections of the upper respiratory tract; Respiratory tract infections; Respiratory and lung infections; Infectious-inflammatory diseases of the upper respiratory tract; Infectious-inflammatory diseases of the upper respiratory tract and ENT organs; Infectious-inflammatory diseases of the upper respiratory tract in adults and children; Infectious-inflammatory diseases of the upper respiratory tract; Infectious inflammation of the respiratory tract; Respiratory tract infection; Qatar upper respiratory tract; Catarrh of the upper respiratory tract; Catarrh of the upper respiratory tract; Catarrhal phenomena from the upper respiratory tract; Cough in diseases of the upper respiratory tract; Cough for colds; ARVI; ARI; ARI with phenomena of rhinitis; Acute respiratory infection; Acute infectious-inflammatory disease of the upper respiratory tract; Acute respiratory disease; Persecution in the throat or nose; Respiratory and viral infections; Respiratory diseases; Respiratory infections; Recurrent respiratory tract infections; Secondary infections with influenza; Influenza states; Feverish conditions for influenza
J22 Acute respiratory infection of lower respiratory tract, unspecified: Bacterial respiratory disease; Bacterial infections of the lower respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory respiratory disease;; Difficult sputum separation in acute and chronic respiratory diseases; Respiratory tract infections; Respiratory and lung infections; Lower respiratory tract infections; Infections of the lower respiratory tract; Infectious inflammation of the respiratory tract; Infectious diseases of the respiratory tract; Infectious diseases of the lungs; Infectious diseases of the respiratory system; Respiratory tract infection; Cough for colds; Pulmonary infection; Acute respiratory tract infection; Acute respiratory viral infection; Acute inflammatory airway disease; Acute respiratory disease; Respiratory infection; Respiratory and viral infections; Respiratory syncytial viral infection in young children; Respiratory diseases; Respiratory infections
J42 Chronic bronchitis, unspecified: Recurrent bronchitis; Asthmatic bronchitis; Asthmatic bronchitis; Bronchitis chronic; Inflammatory respiratory disease; Disease of the bronchi; Qatar smoker; Cough with inflammatory diseases of the lungs and bronchi; Exacerbation of chronic bronchitis; Chronic bronchitis; Chronic Obstructive Pulmonary Diseases; Chronical bronchitis; Chronic bronchitis of smokers; Chronic spasmodic bronchitis; Allergic bronchitis; Bronchitis allergic
K86.1 Other chronic pancreatitis: Chronic pancreatitis; recurrent pancreatitis; Pancreatitis chronic; Exacerbation of chronic pancreatitis; Pancreatitis with an exocrine insufficiency
L20 Atopic dermatitis: Allergic diseases of the skin; Allergic skin disease noninfectious etiology; Allergic skin disease etiology nemikrobnoy; Allergic skin diseases; Allergic skin lesions; Allergic reactions on the skin; atopic dermatitis; Allergic dermatosis; Allergic diathesis; Allergic itching dermatosis; Allergic skin disease; Allergic skin irritation; allergic Dermatitis; atopic Dermatitis; allergic dermatoses; exudative diathesis; Itchy atopic eczema Itchy allergic dermatosis; Allergic skin disease; Cutaneous allergic reaction to drugs and chemicals; Cutaneous reactions to medications; Skin and allergic disease; Acute eczema; common neurodermatitis; Chronic atopic dermatitis; Exudative diathesis
M06.9 Rheumatoid arthritis, unspecified: Rheumatoid arthritis; Pain syndrome in rheumatic diseases; Pain in rheumatoid arthritis; Inflammation in rheumatoid arthritis; Degenerative forms of rheumatoid arthritis; Children's rheumatoid arthritis; Exacerbation of rheumatoid arthritis; Acute articular rheumatism; Rheumatic arthritis; Rheumatic polyarthritis; Rheumatoid arthritis; Rheumatic polyarthritis; Rheumatoid arthritis; Rheumatoid arthritis; Rheumatoid arthritis of active course; Rheumatoid periarthritis; Rheumatoid polyarthritis; Acute rheumatoid arthritis; Acute rheumatism
M13.9 Arthritis, unspecified: Arthritis; Non-infectious arthritis (non-infectious); Arthritis acute; Pain syndrome in acute inflammatory diseases of the musculoskeletal system; Pain syndrome in chronic inflammatory diseases of the musculoskeletal system; Pain with osteoarthritis; Inflammation in osteoarthritis; Inflammatory arthropathy; Inflammatory-degenerative joint disease; Inflammatory disease of the musculoskeletal system; Inflammatory joint disease; Inflammatory diseases of the musculoskeletal system; Destructive arthritis; Diseases of the musculoskeletal system; Diseases of the musculoskeletal system and connective tissue; Infections of the musculoskeletal system; Monoarthritis; Non-rheumatic arthritis; Osteoarthritis; Acute inflammation of the musculoskeletal system; Acute inflammatory disease of the musculoskeletal system; Acute inflammatory condition of the musculoskeletal system; Acute arthritis; Acute osteoarthritis; Post-traumatic osteoarthritis; Reactive arthritis; Chronic inflammatory diseases of the joints; Chronic arthritis; Chronic inflammatory arthritis; Chronic inflammation of the inner layer of the joint capsule; Chronic inflammation of the joint bag; Chronic inflammatory joint disease; Exudative Arthritis
M45 Ankylosing spondylitis: Ankylosing spondylarthrosis; Marie-Strumpel disease; Ankylosing spondylitis; Ankylosing spondylitis; Pain syndrome in acute inflammatory diseases of the musculoskeletal system; Pain syndrome in chronic inflammatory diseases of the musculoskeletal system; Bechterew's disease; Ankylosing spondylitis; Diseases of the spinal column; Rheumatic spondylitis; Bechterew-Marie-Strumpel disease
M79.0 Rheumatism, unspecified: Degenerative rheumatic disease; Degenerative and rheumatic diseases of the tendons; Degenerative rheumatic diseases; Localized forms of rheumatism of soft tissues; Rheumatism; Rheumatism with a pronounced allergic component; Rheumatism of the articular and extraarticular; Rheumatic attack; Rheumatic complaints; Rheumatic diseases; Rheumatic disease; Rheumatic disease of the spine; Relapses of rheumatism; Articular and extra-articular rheumatism; Articular and muscular rheumatism; Articular rheumatism; Articular syndrome with rheumatism; Chronic rheumatic pain; Chronic articular rheumatism; Rheumatoid diseases; Rheumatic diseases of the intervertebral disc
N10 Acute tubulointerstitial nephritis: Tubulointerstitial acute nephritis; Pielit sharp; Pyelonephritis acute; Pyelonephritis bacterial acute; Intermediate Jade; Acute pyelitis; Acute pyelonephritis
N11 Chronic tubulointerstitial nephritis: Nephritis tubulointerstitial chronic; Pyelonephritis chronic; Chronic Pielite; Chronic pyelonephritis
N12 Tubulointerstitial nephritis not specified as acute or chronic: Kidney infections; Infection of the kidneys; Tubulointerstitial nephritis; Uncomplicated pyelonephritis; Interstitial nephritis; Tubular Nephritis; Pyelitis; Pyelonephritis; Pyelocystitis; Postoperative kidney infection; Chronic inflammation of the kidneys
N39.0 Urinary tract infection without established localization: Fungal infections of the urinary tract; Asymptomatic bacteriuria; Bacterial infections of the urinary tract; Bacterial infections of the urinary tract; Bacterial infections of the genitourinary system; Bacteriuria; Bacteriuria asymptomatic; Bacteriuria chronic latent; Asymptomatic bacteriuria; Asymptomatic massive bacteriuria; Inflammatory urinary tract disease; Inflammatory urinary tract disease; Inflammatory diseases of the bladder and urinary tract; Inflammatory diseases of the urinary system; Inflammatory diseases of the urinary tract; Inflammatory diseases of the urogenital system; Fungal diseases of the urogenital tract; Urinary Tract Infections; Urinary Tract Infections; Infections of the urinary system; Urinary tract infections; Urinary Tract Infections; Urinary tract infections caused by enterococci or mixed flora; Urinary tract infections uncomplicated; Urinary tract infections complicated; Infections of the urogenital system; Infections urogenital; Infectious diseases of the urinary tract; Urinary Tract Infection; Urinary tract infection; Urinary system infection; Urinary tract infection; Urinary tract infection; Infection of the urogenital tract; Uncomplicated urinary tract infections; Uncomplicated urinary tract infections; Uncomplicated urinary tract infections; Uncomplicated infections of the genitourinary system; Exacerbation of chronic urinary tract infection; Retrograde kidney infection; Recurrent urinary tract infections; Recurrent urinary tract infections; Recurrent infectious diseases of the urinary tract; Mixed urethral infections; Urogenital infection; Urogenital Infectious-Inflammatory Disease; Urogenital mycoplasmosis; Urologic disease of infectious etiology; Chronic urinary tract infection; Chronic inflammatory diseases of the pelvic organs; Chronic urinary tract infections; Chronic infectious diseases of the urinary system
N41.9 Inflammatory disease of prostate, unspecified
N49 Inflammatory diseases of male genital organs, not elsewhere classified: Bacterial diseases of urogenital tract; Bacterial infections of the genitourinary system; Sexually Transmitted Infections in Men; Infections urogenital; Infectious diseases of the reproductive system; Infectious diseases of genital organs; Chronic inflammatory diseases of the pelvic organs; Infections of the male genital tract
N60.1 Diffuse cystic mastopathy: Benign cystic change in mammary glands; Cystic fibrosis mastopathy; Fibrous-cystic mastopathy; Pre-cancerous condition of mammary glands; Benign mammary gland disease; Benign breast tumor
N73.9 Inflammatory diseases of female pelvic organs, unspecified: Urogenital tract infections; Abscess of pelvic organs; Bacterial diseases of the urogenital tract; Bacterial infections of the genitourinary system; Bacterial infections of the pelvic organs; Intraluminal infections; Inflammation in the area of throat of the uterus; Inflammation of the organs of the small pelvis; Inflammatory disease of the pelvic organs; Inflammatory gynecological diseases; Inflammatory diseases of female pelvic organs; Inflammatory diseases of the pelvic organs; Inflammatory diseases of pelvic organs; Inflammatory infections in the pelvis; Inflammatory processes in the pelvis; Gynecological infection; Gynecological infections; Gynecological infectious diseases; Pyoinflammatory diseases of the pelvic organs; Infections of female genital organs; Infections of the pelvic organs in women; Infections of the pelvic organs; Infectious diseases of the reproductive system; Infectious diseases of genital organs; Infection of female genital organs; Metritis; Acute infection of female genital organs; Acute pelvic inflammatory disease; Tubo-ovarian inflammation; Chlamydial gynecological infections; Chronic inflammatory diseases of the pelvic organs; Chronic inflammatory diseases of appendages; Chronic infections of female genital organs; Pelvic infection
T14.9 Injury unspecified: Pain syndrome after trauma; Pain syndrome with injuries; Pain syndrome with injuries and after surgery; Pain in case of injury; Pain of a traumatic nature; Joint pain with injuries; Postoperative and post-traumatic pain; Pain in case of injury; Pain of traumatic origin; Severe pain syndrome of traumatic origin; Deep tissue damage; Deep scratches on the trunk; Closed injury; Minor Household Injuries; Minor skin damage; Violations of the integrity of soft tissues; Uncomplicated trauma; Extensive traumatic injury; Acute pain syndrome of traumatic origin; Edema with trauma; Postponed sports injuries; Post-traumatic pain; Soft tissue injuries; Joint wounds; Sports injuries; Injury; Traumatic pain; Traumatic pains; Traumatic infiltrate; Injuries to sports
Z100 * CLASS XXII Surgical practice: Abdominal surgery; adenomectomy; Amputation; Coronary angioplasty; Angioplasty of the carotid arteries; Antiseptic skin treatment for wounds; Antiseptic Hand; Appendectomy; atherectomy; Balloon coronary angioplasty; Vaginal hysterectomy; The coronary bypass; Interventions in the vagina and cervix; Interventions on the bladder; Intervention in the mouth; Restoration and reconstructive surgery; Hand hygiene of medical personnel; Gynecologic surgery; Gynecological intervention; Gynecological surgery; Hypovolemic shock during operations; Disinfection of purulent wounds; Disinfection of wounds edges; Diagnostic intervention; Diagnostic procedures; Cervical Diathermocoagulation; Long-surgery; Replacing the fistula catheters; Infection in orthopedic surgery; Artificial heart valve; cystectomy; Short-term outpatient surgery; Short-term operation; Short surgical procedures; Krikotireotomiya; Blood loss during surgery; Bleeding during surgery and in the postoperative period; Kuldotsentez; laser photocoagulation; laser coagulation; retinal laser coagulation; Laparoscopy; Laparoscopy in Gynecology; CSF fistula; Small gynecological operations; Small surgical procedures; Mastectomy and subsequent plastic; mediastinotomy; Microsurgical operations on the ear; Mukogingivalnye operation; suturing; Minor surgery; neurosurgical operation; Immobilization of the eyeball in ophthalmic surgery; testectomy; pancreatectomy; Perikardektomiya; The period of rehabilitation after surgery; The period of convalescence after surgery; Percutaneous transluminal coronary angioplasty; Pleural thoracentesis; Pneumonia postoperative and posttraumatic; Preparation for surgical procedures; Preparation for surgery; Preparation of the surgeon's hands before surgery; Preparation of the colon for surgical procedures; Postoperative aspiration pneumonia in neurosurgical and thoracic surgery; Postoperative nausea; Postoperative bleeding; postoperative granuloma; postoperative shock; The early postoperative period; myocardial revascularization; Radiectomy; gastric Resection; bowel resection; uterine Resection; liver Resection; enterectomy; Resection of part of the stomach; Reocclusion of the operated vessel; Bonding tissues during surgical procedures; Removal of sutures; Condition after eye surgery; Condition after surgery; Condition after surgery in the nasal cavity; Condition after gastrectomy; Status after resection of the small intestine; Condition after tonsillectomy; Condition after removal of the duodenum; Condition after phlebectomy; Vascular surgery; Splenectomy; Sterilization of surgical instruments; Sterilization of surgical instruments; sternotomy; Dental surgery; Dental intervention in periodontal tissues; strumectomy; Tonsillectomy; Thoracic surgery; Thoracic surgery; total gastrectomy; Transdermal intravascular coronary angioplasty; Transurethral resection; Turbinektomiya; Removal of a tooth; cataract surgery; Removal of cysts; tonsillectomy; Removal of fibroids; Removing the mobile primary teeth; Removing polyps; Removing broken tooth; Removal of the uterus body; Removal of sutures; Fistula likvoroprovodyaschih ways; Frontoetmoidogaymorotomiya; Surgical infection; Surgical treatment of chronic limb ulcers; Surgery; The surgery in the anal area; The surgery on the colon; Surgical practice; The surgical procedure; Surgical interventions; Surgery on the gastrointestinal tract; Surgical procedures on the urinary tract; Surgical procedures on the urinary system; Surgical intervention of the genitourinary system; Surgical procedures on the heart; Surgical manipulation; surgery; Surgery on the veins; Surgical intervention; Vascular surgery; Surgical treatment of thrombosis; Surgery; cholecystectomy; Partial gastric resection; hysterectomy; Percutaneous transluminal coronary angioplasty; Percutaneous transluminal angioplasty; Coronary artery bypass; tooth Extirpation; Extirpation of milk teeth; pulpectomy; pulsative cardiopulmonary bypass; tooth Extraction; teeth Extraction; cataract extraction; Electrocoagulation; endourological intervention; episiotomy; Etmoidotomiya; Complications after tooth extraction
Z51.0 Radiotherapy course: Supplement to external radiation therapy; Local X-Ray Irradiation; Radiation therapy; Brain edema associated with radiation therapy; Lesion in radiation therapy; Radiotherapy
Z51.1 Chemotherapy for neoplasm: Cystitis hemorrhagic, caused by cytostatics; Urotoxicity of cytostatics
Tablets, covered with enteric-coated shell 1 tab.
Pancreatin 345 prot. EF EF
Papain 90 IU (FIP)
Rutoside trihydrate 50 mg
Bromelain 225 units (FIP)
Trypsin 360 units (FIP)
Lipase 34 units (FIP)
Amylase 50 units (FIP)
Chymotrypsin 300 units (FIP)
Auxiliary substances: lactose monohydrate; corn starch; Magnesium stearate; Stearic acid; purified water; Silicon dioxide highly dispersed; Sucrose; talc; Calcium carbonate; Methacrylic acid and methyl methacrylate copolymer (1: 1); resin; Titanium dioxide; White dye; Yellow-orange colorant S (E110); Crimson dye 4 R (E124); Povidone; Macrogol 6000; Triethyl citrate; vanillin; Wax bleached; Carnauba wax
Description of dosage form
The biconvex round tablets are covered with an enteric-soluble shell of a red-orange color, with a smooth surface and a characteristic odor; Fluctuations in the color of the shell from red-orange to red are allowed.
Mode of action - fibrinolytic, anti-inflammatory, immunomodulating, anti-edematous, antiaggregant.
WOBENZYM is a combination of highly active proteolytic enzymes (proteases) of plant and animal origin showing stable pharmacological activity. In combination, the enzymes exert a pleiotropic (multiple) effect, having various effects on various target organs and biochemical processes. Protease drugs realize their systemic effects through immunomodulatory, antiaggregant, fibrinolytic, decongestant, thrombolytic and secondary analgesic actions. An important ability of enzymes immobilized by endogenous antiproteases is the ability to move in the vascular bed and be present in various organs and tissues, which is of great therapeutic importance in systemic inflammatory processes and lesions. In the preparation, the ability of the enzymes of plant and animal origin to cooperate and synergize is realized, due to which their action is amplified and complemented.
Entering the body, the tablets of the drug, covered with a protective intestine-soluble membrane, transit the upper sections of the digestive tract, not injuring the stomach and not participating in digestion. The protective coating of tablets dissolves in the small intestine, and the enzymes of the drug migrate through the intestinal wall (endocytosis, pinocytosis).
Some of the proteolytic enzymes of the drug are absorbed by resorption of intact molecules and form complexes with blood transport proteins - antiproteases (α-2-macroglobulin and α-1-antitrypsin). When combined with antiproteases, the proteolytic enzymes of the preparation alter the conformational structure of the transport macromolecules of antiproteases, as a result of which the antiproteases pass into an active form capable of regulating the level of cytokines, growth factors and hormones in the vascular bed.
The formation of the protease-antiprotease complex allows to slow the excretion of exogenous proteolytic enzymes of the drug from the body and increase the time of their circulation in the bloodstream. In the complex there is no irreversible inactivation of exogenous enzymes, they retain their activity and reactivity with respect to specific substrates affinity for proteases.
Antiprotease (α-2-macroglobulin) masks the antigenic determinants of the protease drug macromolecules, which ensures the movement of enzymes along the vasculature without the appearance of an allergic reaction of the immune system and their delivery to remote sites to the focus of inflammation, regardless of the localization of the pathological process in the body.
Under the influence of enzymes of the drug, the activated form of α-2-macroglobulin acquires the ability to regulate the level of proinflammatory cytokines and growth factors, carrying out their sorption, transport and clearance. Thus, the enzymes of the drug indirectly, through the activation of endogenous antiproteases, can regulate the transition of the proinflammatory immune response to anti-inflammatory. Proteolytic enzymes interrupt the pathological cascade of inflammation, optimize the course of inflammation and prevent the transition of the inflammatory process to a chronic stage.
Activated antiproteases regulate the level of the transforming growth factor β (TGF-β) in the circulatory bed due to its sorption and elimination. TGF-β has an autocrine nature of regulation, which makes it difficult to control, and is responsible for replacing damaged parts of organs with connective tissue. Enzymes of the drug indirectly through antiproteases lower the level of TGF-β, thus, Regulating reparative processes, physiological growth of connective tissue and scar formation, while preventing the formation of a keloid scar and the development of a commissural disease.
Part of the proteolytic enzyme of the drug remaining in the intestine enters the digestive reaction, improves the cleavage of proteins, fats, carbohydrates and other substrates, and also facilitates the restoration of the intestinal ecology and microbial balance between the autochthonous (related) and opportunistic microflora.
Enzymes of the drug have a positive effect on the course of the inflammatory process, limit the pathological manifestations of autoimmune and immunocomplex processes, restoring the immunological reactivity of the organism. Protease drugs accelerate the decay of inflammatory mediators, normalize the activity of the complement system, stimulate and regulate the level of functional activity of monocyte-macrophages, natural killer cells and activate the antitumor immunity. The drug reduces the level of proinflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α, INF-γ) and promotes the production of anti-inflammatory cytokines (IL-4, IL-10), regulates Ig and antibodies level, about. Providing a multilateral immunomodulatory effect, increasing the activity of phagocytes and stimulating interferonogenesis.
Under the influence of proteases, the amount of circulating immune complexes (antigen-antibody) and membrane deposits of immune complexes decreases with the acceleration of their elimination (excretion) from tissues due to shedding (splitting) of immune complexes and decrease in the density of adhesive molecules.
The drug reduces the infiltration of interstitium by plasma proteins, increases the elimination of protein detritus (cellular fragments) and deposits of fibrin in the inflammation zone, accelerates the lysis of toxic products and necrotic tissues, thus, Improving trophic tissue, helping to reduce edema and improve the penetration of drugs into the focus of inflammation.
The enzymes of the preparation optimize the physiological course of the reparative processes, accelerate the resorption of hematomas and edema, normalize the permeability of the vessel walls, improve microcirculation and trophic processes in the affected area, reduce oncotic pressure in the tissues, thus, Accelerating healing and recovery.
The drug reduces the concentration of thromboxane and platelet aggregation (clumping), reduces the expression of adhesion molecules and the adhesion of blood cells to the endothelium, increases the ability of red blood cells to change their shape (deformability), improving their plasticity for passage of bifurcations of blood vessels, which facilitates efficient delivery of oxygen to the tissue.
The drug activates the anticoagulant system of blood, helps to restore the number of discocytes, reduces the number of activated platelet forms, reduces the total number of platelet microaggregates, normalizes blood viscosity, thus, Improving rheological properties of blood and microcirculation in tissues. Proteolytic enzymes of the drug increase fibrinolytic activity of blood plasma, activate endothelial function, improve lymph flow, supply tissues with oxygen and improve metabolism in the body.
The drug reduces the risk of developing unwanted effects associated with taking hormonal drugs (hypercoagulation, platelet activation, thrombosis, thickening of the blood).
The drug has a pronounced antioxidant effect, reduces lipid peroxidation, normalizes lipid metabolism. Proteolytic enzymes of the drug reduce the level of endogenous cholesterol, increase the level of HDL, lower the level of LDL, so. Exhibiting antiatherogenic effect. The drug improves the metabolism of polyunsaturated fatty acids, increases the antioxidant activity of plasma, reduces oxidative stress and helps prevent the development of systemic inflammation.
Proteolytic enzymes of the drug interrupt communication and intercellular interaction between bacteria, make it difficult to form membranes and matrix biofilms, disrupt the growth of microbial colonies in biofilms (in vitro). Thus, drug enzymes create favorable conditions for the penetration of antibiotics into microbial communities (biofilms), increasing the effectiveness of antibiotic therapy. Protease drugs interrupt the frequency of transfer of resistance factors to antibiotics (plasmid genes) between bacteria in microbial colonies, while reducing the risk of resistance (resistance) to antibiotics. Infringement by enzymes of cooperation and communications between bacteria on formation of a protective mechanism - biofilms, makes bacteria more vulnerable to antibiotics. The drug creates conditions for increasing the concentration of antibiotics in the focus of infection, which increases the effectiveness of antibiotic therapy.
The enzymes of the drug reduce the undesirable side effects of antibiotic therapy (dysbiosis, irritable bowel syndrome) by improving food digestion, substrate cleavage, normalization of microflora and restoration of endoecology of the intestine.
Protease drugs activate the natural mechanisms of nonspecific defense, increases the production of interferons, IgA and lysozyme, thus, Implementing antiviral and antimicrobial actions.
Indication of the Wobenzym
The drug is used as an integral part of complex therapy of the following diseases:
Angiology - thrombophlebitis, postthrombophlebitic disease, endarteritis and obliterating atherosclerosis of lower extremity arteries, prevention of recurrent phlebitis, lymphatic edema;
Gastroenterology - chronic inflammatory diseases of the digestive tract, hepatitis, dysbiosis;
Gynecology - acute and chronic infectious and inflammatory diseases of the genitals: salpingoophoritis, endometritis, cervicitis, vulvovaginitis; Gestosis, mastopathy, decreased frequency and severity of undesirable effects of hormone replacement therapy, complex therapy for miscarriage II and III trimester, sexually transmitted infections, in combination with antibiotics: chlamydia, ureaplasmosis, mycoplasmosis;
Dermatology - atopic dermatitis, acne, itchy dermatitis;
Cardiology - angina pectoris, subacute stage of myocardial infarction (to improve rheological properties of blood and trophic processes of the myocardium);
Neurology - multiple sclerosis, chronic disorders of cerebral circulation;
Nephrology - pyelonephritis, glomerulonephritis in combination with antibiotics;
Oncology - improving the tolerability of chemo- and radiotherapy and reducing the risk of developing concomitant infectious complications;
Otorhinolaryngology - sinusitis, sinusitis, otitis, laryngitis in combination with antibiotics;
Ophthalmology - uveitis, iridocyclitis, hemophthalmus, diabetic retinopathy, glaucoma, ophthalmosurgery, prevention of complications after operations;
Pediatrics - atopic dermatitis, infectious and inflammatory diseases of the respiratory tract (inflammation of the upper and lower respiratory tract, pneumonia), prevention and treatment of postoperative complications (suppuration and local edema, poor wound healing, adhesions);
Pulmonology - bronchitis, tracheobronchitis, obstructive bronchitis, pneumonia, tuberculosis;
Rheumatology - rheumatoid arthritis, reactive arthritis, osteoarthritis, juvenile rheumatoid arthritis;
Stomatology - infectious-inflammatory diseases of the oral cavity;
Traumatology - trauma, chronic post-traumatic processes, inflammation of soft tissues, trauma in sports medicine;
Urology - cystitis, cystopyelitis, prostatitis, sexually transmitted infections (in combination with antibiotics);
Surgery - prevention of postoperative complications (inflammation, thrombosis, edema), post-traumatic and lymphatic edema;
Endocrinology - diabetic angiopathy, diabetic retinopathy, autoimmune thyroiditis.
Disruption of adaptation and acclimatization, post-stress disorders;
Disorders of microcirculation, vascular accidents;
The development of viral infections and their complications;
Undesirable effects of hormone replacement therapy;
Dysbiotic disorders with antibacterial therapy.
Individual intolerance of individual components of the drug;
Diseases associated with increased bleeding probability (hemophilia, thrombocytopenia);
Children under 5 years.
Application in pregnancy and breastfeeding
Pregnancy and lactation are not a contraindication for the use of the drug. Pregnant women are recommended to use the drug as part of the complex therapy of miscarriage from the second trimester of pregnancy.
Dosage and duration of use of the drug to pregnant women should be agreed with the doctor.
The drug is well tolerated under the condition of adherence to the regimen: tablets should be taken without sniffing, 30 minutes before meals or 2 hours after eating, squeezed with water.
In some cases: nausea, vomiting, diarrhea, severity in the stomach, minor changes in the consistency and odor of stool, skin rashes in the form of urticaria, allergies to certain components of the drug that occur with a lower dose or drug withdrawal.
The withdrawal and addiction syndrome was not observed even with prolonged treatment with high doses of the drug.
If there are other side effects not noted in the instructions, it is recommended to cancel the medication, consult a doctor and send information about the adverse reaction to the Representative Office of the manufacturer in Russia (the address is listed at the end of the manual).
When the drug is taken with other medicines, cases of incompatibility are not described.
Dosing and Administration
Take no snacking, at least 30 minutes before meals or 2 hours after eating, squeezed with water (150 ml).
Adults. Traditionally, the drug is prescribed in a minimum therapeutic dosage of 3 tablets. 3 times a day from 2 to 5 weeks.
With an average activity of the disease, WOBENZYM is prescribed in a dose of 5 tablets. 3 times a day, course from 2 to 4 weeks. When the patient's condition improves, the dose of the drug from the 2nd week can be reduced to 3 tablets. 3 times a day. To achieve a long-term effect, it is recommended to repeat courses of the drug for 1.5-2 months with a two-week break.
With high activity of the disease, WOBENZYM is prescribed in a dose of 7 tablets. 3 times a day, the course - 3 weeks. When the condition improves, the dose of the drug can be reduced from the 2nd week to 3 tablets. 3 times a day with the continuation of the course to 1.5 months. The duration of treatment is determined by the doctor.
In chronic long-term diseases, WOBENZYM can be used according to indications for courses from 3 to 6 months with interruptions 2-4 weeks.
At operations. When carrying out scheduled operations, the drug is used to prevent the development of complications (inflammation, keloid scar, adhesions). The drug is prescribed before surgery for 3 tables. 3 times a day for 5 days; 3 days prior to surgery, the drug is withdrawn.
With antibiotics. To increase the effectiveness of antibiotics and reduce the severity of side effects, as well as the prevention of dysbiosis, the drug is prescribed for the entire course of antibiotic therapy in a dose of 5 tablets. 3 times a day. After completing the course of antibiotics to restore the microflora of the intestinal WOBENZYM, it is recommended to take 3 tablets each. 3 times a day for 7-14 days.
With chemotherapy. To prevent infectious complications, improve tolerability and improve the quality of life, the drug is prescribed as a "cover" therapy during chemotherapy and radiotherapy according to 5 tablets. 3 times a day before the end of chemotherapy and radiation therapy. After the end of the course of chemotherapy, the drug is prescribed to restore immunity to 3 tablets. 3 times a day; Course - 3 weeks.
For prevention. When using the drug WOBENZYM for preventive purposes, to increase the threshold of adaptation, resistance to diseases and reduce the risk of diseases and vascular accidents, the drug is recommended to use 2-3 tablets. 3 times a day. The course is from 3 weeks to 1.5 months with a repeat 2-3 times a year.
Children. At an early age, children experience difficulty in swallowing tablets, therefore it is recommended that WOBENZYM be prescribed to children from the age of 5. The drug is prescribed from the calculation of 1 table. For 6 kg of the child's weight 2 times a day. Take the drug without cracking, 30 minutes before eating, or 2 hours after eating, squeezed with water. The duration of the course of treatment can be from 2 to 5 weeks, depending on the diagnosis and condition of the child, and is determined by the doctor.
The dose of the drug should be calculated individually for each child up to 12 years. From the age of 12 the drug is prescribed according to the scheme for adults: 3 tablets. 3 times a day; Course - from 2 to 5 weeks, the duration of treatment is determined by a doctor and depends on the severity of the disease.
In infectious diseases in children, the drug is recommended to be taken together with antibiotics in order to increase their effectiveness throughout the course of antibiotic therapy in dosage according to the age and weight of the child.
To restore the ecology of the intestine and increase immunity after completion of antibacterial and etiotropic anti-infective therapy, the drug is prescribed for 1 table. 2 times a day, from 12 years the drug is prescribed for 2 tablets. 2 times a day; The recommended course is from 1 to 3 weeks, the duration of the drug is determined by the doctor.
With relapsing inflammatory diseases in a patient who is often and long-term ill, the drug is recommended to take 2 tablets each. 2 times a day by a course of 3-6 weeks or in a dosage according to age and weight to the child.
To achieve a stable remission and improve the condition of often and long-term sick children, it is recommended that several repeated courses of the drug be given per year for 3-6 weeks with a 1-2-week break. Dosage and duration of use of the drug in children who are often ill depends on the severity of the disease and is determined by the doctor.
Cases of drug overdose are unknown.
It should be borne in mind that at the beginning of taking the drug symptoms of the disease can worsen; In such cases, treatment should not be interrupted, but a temporary reduction in the dose of the drug is recommended.
In infectious diseases, the drug does not replace antibiotics, but increases their effectiveness, increasing the concentration of antibiotics in tissues, microbial colonies and a hotbed of inflammation.
Influence on the ability to drive a car or perform work that requires an increased speed of physical and mental reactions. The drug is not doping and does not have a negative impact on driving and performance of work requiring high speed of mental and physical reactions.
Tablets, covered with enteric coating: in blisters of 20 pcs .; In vials of HDPE for 800 pcs .; In a box of cardboard 2 or 10 blisters.
Mukos Emulsions GmbH.
D-13509, Mirausstrasse, 17, Berlin, Germany.
MUKOS Pharma GmbH & Co., KG.
D-13509, Mirausstrasse, 17, Berlin, Germany.
For additional information and with complaints, contact the Representative Office of MUKOS Pharma
Conditions of supply of pharmacies
Storage conditions of the drug Wobenzym
In a dry place, at a temperature of 15-25 ° C. Do not require special precautions when destroying an unused product with expired shelf life.
Keep out of the reach of children.
Shelf life of the drug Wobenzym
2.5 years. Do not use the product after the expiration date indicated on the blister and the box expiration date.
Do not use after the expiry date printed on the package.